Clinical Trials Logo
  1. Home
  2. End-Stage Kidney Disease
  3. NCT05715814

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis — CANARY  

End Stage Kidney Disease Clinical Trial

Official title:
A Single Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of Once Daily 25mg Empagliflozin in Patients on Peritoneal Dialysis With Residual Kidney Function

Clinical Trial Summary

The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).

Clinical Trial Description

The importance of RKF on the survival of patients on PD has been demonstrated in several observational studies. Despite this, there are limited pharmacological interventions available to slow the loss of RKF in these patients. There is an unmet need for novel cardiovascular and kidney protective strategies for patients on renal replacement therapies, including PD. SGLT2 inhibitors have been shown to have both cardiovascular and kidney protective effects in individuals with kidney disease, with and without diabetes. These benefits have been attributed to diverse mechanisms and kidney benefits have been largely attributed to reductions in intraglomerular pressure at the single nephron level, reversibly lowering GFR in the short-term with long-term benefits. However, the beneficial effects of SGLT2 inhibitors have never been studied in patients on dialysis. The CANARY study will provide insight into the safety and mechanisms of SGLT2 inhibitors in individuals on dialysis with RKF, with and without type 2 diabetes, over a period of 2 weeks. Demonstrating that protective mechanisms associated with SGLT2 inhibitors are intact in patients on PD with RKF would provide a strong rationale for a larger clinical trial to explore the use of these novel drugs in this unique clinical application. Additionally, our proposed study would provide timely mechanistic data to inform clinical decisions in the context of other large clinical trials such as EMPA-KIDNEY. These findings would help physicians make decisions on leaving patients on SGLT2 inhibitors even beyond end-stage kidney disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05715814
Study type Interventional
Source University Health Network, Toronto
Contact Vesta Lai
Phone 416-340-4800
Email vesta.lai@uhn.ca
Status Not yet recruiting
Phase Phase 3
Start date February 1, 2024
Completion date April 1, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04319185 - Assisted Peritoneal Dialysis: A Feasibility Study N/A
Recruiting NCT06056739 - Alio WEAR Study: Long-term Wear of the Alio Platform N/A
Recruiting NCT05311956 - Pain Reduction Using NEurostimulation Study N/A
Active, not recruiting NCT05485961 - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis Phase 2/Phase 3
Completed NCT02939586 - The Effect of Haemodialysis in Sleep Apnoea N/A
Completed NCT00792454 - Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program N/A
Recruiting NCT03586518 - Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients
Completed NCT02513303 - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Phase 3
Recruiting NCT05642156 - Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis N/A
Not yet recruiting NCT05774392 - An Observational Study of Patients With Chronic Kidney Disease
Completed NCT01877863 - The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients N/A
Completed NCT01859871 - Evaluation of a Website on Living Kidney Donation for Hispanics N/A
Completed NCT00649298 - A Clinical Trial of IntensiVE Dialysis Phase 4
Recruiting NCT05836220 - Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 Phase 3
Completed NCT04912024 - Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
Not yet recruiting NCT06356168 - Virtual Reality in End Stage Kidney Disease N/A
Not yet recruiting NCT05558267 - Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease N/A
Completed NCT01530945 - Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease N/A
Completed NCT04815850 - Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
Recruiting NCT05738330 - Symptom Monitoring in Hemodialysis N/A